Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-dose chemotherapy for solid tumors: results of the EBMT.
Rosti G, Ferrante P, Ledermann J, Leyvraz S, Ladenstein R, Koscileniak E, Crown J, Dazzi C, Cariello A, Marangolo M. Rosti G, et al. Among authors: dazzi c. Crit Rev Oncol Hematol. 2002 Feb;41(2):129-40. doi: 10.1016/s1040-8428(01)00150-0. Crit Rev Oncol Hematol. 2002. PMID: 11856589 Review.
Prevention and therapy of neutropenia in elderly patients.
Rosti G, Kopf B, Cariello A, Monti M, Dazzi C, Papiani G, Giovanis P, De Giorgi U, Marangolo M. Rosti G, et al. Among authors: dazzi c. Crit Rev Oncol Hematol. 2003 Jun;46(3):247-53. doi: 10.1016/s1040-8428(03)00024-6. Crit Rev Oncol Hematol. 2003. PMID: 12791424 Review.
High-dose chemotherapy for breast cancer.
Dazzi C, Cariello A. Dazzi C, et al. N Engl J Med. 2003 Oct 9;349(15):1476-9; author reply 1476-9. N Engl J Med. 2003. PMID: 14535260 No abstract available.
Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results.
Passardi A, Fanini F, Turci L, Foca F, Rosetti P, Ruscelli S, Casadei Gardini A, Valgiusti M, Dazzi C, Marangolo M. Passardi A, et al. Among authors: dazzi c. Oncologist. 2017 Aug;22(8):886-e79. doi: 10.1634/theoncologist.2017-0206. Epub 2017 Jun 7. Oncologist. 2017. PMID: 28592624 Free PMC article. Clinical Trial.
Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.
Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, Capelli L, Casanova C, De Luigi N, Mariotti M, Gamboni A, Chiari R, Bennati C, Calistri D, Ludovini V, Crinò L, Amadori D, Ulivi P. Canale M, et al. Among authors: dazzi c. Clin Cancer Res. 2017 May 1;23(9):2195-2202. doi: 10.1158/1078-0432.CCR-16-0966. Epub 2016 Oct 25. Clin Cancer Res. 2017. PMID: 27780855
Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?
Ulivi P, Delmonte A, Chiadini E, Calistri D, Papi M, Mariotti M, Verlicchi A, Ragazzini A, Capelli L, Gamboni A, Puccetti M, Dubini A, Burgio MA, Casanova C, Crinò L, Amadori D, Dazzi C. Ulivi P, et al. Among authors: dazzi c. Int J Mol Sci. 2014 Dec 31;16(1):747-57. doi: 10.3390/ijms16010747. Int J Mol Sci. 2014. PMID: 25561229 Free PMC article.
103 results